Introduction
============

Chronic obstructive pulmonary disease is finally gaining the attention needed to begin to solve this common problem. It is defined as chronic airflow obstruction that is progressive and only partly reversible ([@b60-copd-1-3]; [@b32-copd-1-3]). COPD includes chronic bronchitis, emphysema, and chronic asthmatic bronchitis (defined further below). Today, COPD is the fourth most common cause of death in the USA, and is the only disease state that is rising in morbidity and mortality amongst the top five killers. It resulted in a \$32.1 billion loss to the USA economy in direct and indirect costs in 2003, and by 2020 is expected to become the third most common cause of death ([@b52-copd-1-3]). Approximately 16 million adult Americans have COPD. Probably an equal number have asymptomatic or even symptomatic disease but are not diagnosed or treated ([@b45-copd-1-3]). Interest in COPD is a recent development and few know the origins of this interesting disease spectrum. This review offers a glimpse into the rich history in the development of our present understanding of COPD.

Early historical landmarks
==========================

Some of the earliest references to the description of emphysema include: [@b9-copd-1-3] ([@b9-copd-1-3]); [@b50-copd-1-3] description of 19 cases in which the lungs were "turgid", particularly from air; and Baille's illustrations of the emphysematous lung, thought to be that of Samuel Johnson (Baillie 1789; [@b8-copd-1-3]).

The beginnings of our clinical understanding of the chronic bronchitis component of COPD can be traced to [@b3-copd-1-3], who used the word catarrh to refer to the chronic cough and mucus hypersecretion that are cardinal symptoms. He described bronchiolitis and chronic bronchitis as disabling disorders ([@b3-copd-1-3]).

The emphysema component of disease was beautifully described by [@b41-copd-1-3] in his *Treatise of diseases of the chest*. Laënnec, a clinician, pathologist, and inventor of the stethoscope, did careful dissections of patients that he had studied during life. He recognized that emphysema lungs were hyperinflated and did not empty well ([@b41-copd-1-3]).

In his *A treatise on the diseases of the chest and on mediate auscultation* (1837, p 81) Laënnec wrote on emphysema:

> The disease which I designate by this title is very little known and has not hitherto been correctly described by any author. I for a long time thought it very uncommon, because I had observed only a few cases of it: but since I have made use of the stethoscope, I have verified its existence as well on the living as the dead subject, and am led to consider it as by no means infrequent. I consider many cases of asthma, usually deemed nervous, as depending on this cause. The chief reason of this affection having been so completely overlooked is, that it is in some sort merely the exaggeration of the natural condition of the viscus.

In this era, smoking was rare, but it is a fact that emphysema may occur in non-smokers, particularly with a familial predisposition or from environmental-provoking factors. Laënnec continued:

> In opening the chest, it is not unusual to find that the lungs do not collapse, but they fill up the cavity completely on each side of the heart. When experienced, this will appear full of air . . . . The bronchus of the trachea are often at the same time a good deal filled with mucous fluid ([@b41-copd-1-3], p 89).

Thus Laënnec had described a combination of emphysema and chronic bronchitis.

John Hutchinson invented the spirometer in 1846 ([@b39-copd-1-3]). The spirometer is key to the diagnosis and management of COPD, yet its use is still poorly applied to the diagnosis and management of COPD in most locations in the world today. Hutchinson's instrument only measured vital capacity. It took another 100 years for Tiffeneau to add the concept of timed vital capacity as a measure of airflow, for spirometry to become complete as a diagnostic instrument ([@b98-copd-1-3]).

[@b57-copd-1-3] says little about emphysema. Osler believed emphysema was caused by excessive pressure in the alveoli ([@b57-copd-1-3]), and reference to the spirometer cannot be found in this classic text. In 1912, another author did not mention spirometry, but shows a nice picture of the sphygmomanometer, invented by Rico Rossi in 1896, and excellent quality EKG strips are shown ([@b10-copd-1-3]). This occured 50 years after Hutchinson's invention. A textbook of *Disease in the chest* in 1918 makes only brief mention of spirometry with no illustrations ([@b55-copd-1-3]).

Gaensler introduced the concept of the air velocity index based on Tiffeneau's work and later the forced vital capacity, which is the foundation of the FEV~1~ and FEV~1~/FVC percent ([@b30-copd-1-3], [@b31-copd-1-3]).

In 1944, one of the great teachers of emphysema, Ronald Christie, suggested that "The diagnosis should be considered certain when dyspnea on exertion, of insidious onset, not due to bronchospasm, or left ventricular failure, appears in a patient who has some physical signs of emphysema together with chronic bronchitis and asthma" ([@b20-copd-1-3], p 145). It is clear from this statement that Christie recognized the individual components of COPD and relied on the history and physical examination for his diagnosis. Oswald described the clinical features of 1000 cases of chronic bronchitis in 1953 ([@b58-copd-1-3]).

[@b5-copd-1-3] edited the first comprehensive text book, *Pulmonary emphysema*, which nicely describes the treatment of the era. These two physicians were early champions of treatment for emphysema. Contributors to this book included Dayman, the first to recognize the spirometric and flow volume patterns indicative of dynamic expiratory airway collapse in emphysema; Dickerson Richards, Nobel Laureate, who wrote on the pulmonary circulation and cor pulmonale; Reuben Cherniack, who described respiratory acidosis and has made major contributions to our understanding of the diagnosis and treatment of emphysema for over half a century; and Menelee and Callaway, who described pulmonary function tests in emphysema patients. In all, 17 leading clinicians and clinical scientists contributed to this classic volume of the 1950s.

The first edition of [@b37-copd-1-3] (now Murray and Nadel) *Textbook of respiratory medicine* shows a nice picture of a Collins 13.5 liter recording spirometer, and shows capacity spirograms that demonstrate airflow limitation in emphysema.

Definitions
===========

Two landmark meetings: The CIBA Guest Symposium in 1959 ([@b21-copd-1-3]; [@b26-copd-1-3]) and the American Thoracic Society Committee on Diagnostic Standards in 1962 defined the components of COPD, which are the foundation for our definitions today ([@b22-copd-1-3]). The American Thoracic Society (ATS) defined chronic bronchitis in clinical terms including chronic cough lasting at least three months for at least two years. By contrast, the ATS defined emphysema in anatomic terms of enlarged alveolar spaces and loss of alveolar walls. Neither definition used any physiologic criteria. Asthma was described as a state of airway hyperresponsiveness to a variety of stimuli. Asthmatic bronchitis was considered an overlapping condition ([@b22-copd-1-3]). (The author had the privilege of attending the deliberations of the ATS committee as a Resident in Medicine in 1962 in Memphis Tennessee during the time of the annual VA-Armed Forces Annual Conference on the Treatment of Tuberculosis.) Many other attempts to define COPD have not improved on these basic definitions, except that COPD is now defined in functional terms.

Other acronyms that predated the COPD designation were chronic obstructive bronchopulmonary disease, chronic airflow obstruction, chronic obstructive lung disease, nonspecific chronic pulmonary disease, and diffuse obstructive pulmonary syndrome. William Briscoe is believed to be the first person to use the term COPD in discussion at the 9th Aspen Emphysema Conference. This term became established and today we refer to COPD as the designation of this growing health problem ([@b12-copd-1-3]).

Pathology
=========

In the past 50 years, the pathology of emphysema and other components of COPD have filled textbooks ([@b77-copd-1-3]; [@b35-copd-1-3]; [@b97-copd-1-3]). Loss of alveolar walls (emphysema), mucous gland hyperplasia (Reid index) in large conducting airways ([@b76-copd-1-3]), and bronchiolitis with fibrosis have been extensively documented and illustrated. [@b97-copd-1-3] cites Jethro Gough and his first use of whole lung thin sections to illustrate the various types of emphysema ([@b33-copd-1-3]; [@b97-copd-1-3]).

The Dutch hypothesis and British hypothesis in pathogenesis were early basic concepts. The Dutch hypothesis presented the concept of genetically determined bronchial hyperreactivity in COPD ([@b56-copd-1-3]). The British hypothesis proposed that repeated chest infections and air pollution contributed to the pathogenesis of chronic bronchitis ([@b93-copd-1-3]; [@b84-copd-1-3]). Both hypotheses are probably correct, and both bronchial hyperreactivity and chest infections plus irritant exposure are important in pathogenesis.

Experimental emphysema
======================

Many disease models have yielded clues to cause, pathophysiology, clinical manifestations, and therapeutic targets. Early attempts to produce experimental emphysema used obstructive devices placed in the major airways or trachea to attempt to reproduce hyperinflation. The author spent a research summer employing the use of a venturi device (that had greater expiratory than inspiratory resistance) placed in the trachea of dogs. This study did not produce hyperinflation or emphysema. In fact the dogs developed reduced functional residual capacity with the tracheal obstruction, a fact of tracheal obstruction that was not known by this naïve student investigator. A presentation on experimental emphysema at the First Aspen Emphysema Conference in 1958 documents this work and that of earlier investigators ([@b27-copd-1-3]).

The first credible production of emphysema was by [@b34-copd-1-3], who instilled pancreatic extracts (papain) into the airways of guinea pigs to cause destruction of alveoli and hyperinflation ([@b34-copd-1-3]). This was somewhat of a fortuitous discovery, since he was not trying to produce emphysema, but was hoping to determine the effect of papain on the fibrosis associated with experimental silicosis that he was studying. Gross's work produced emphysema, due to proteolytic damage of elastin and thus was the forerunner of the protease -- antiprotease therapy of the pathogenesis, as described by [@b43-copd-1-3] in Sweden with alpha-one-antitrypsin deficiency and emphysema. Other investigations also used elastases to produce experimental emphysema ([@b91-copd-1-3]). Many genetic, infectious, and immunologic models in small animals followed and continue to be investigated at the present time. A recent model employing methylprednisolone to produce emphysema in rats induces matrix metalloproteinase and can be prevented by a metal proteinase inhibitor ([@b19-copd-1-3]). The concept that emphysema is an autoimmune vascular disease has been offered as one pathway in pathogenesis ([@b100-copd-1-3]). Studies in experimental emphysema, though possibly species specific, are useful in suggesting new therapeutic targets.

The Aspen emphysema conferences
===============================

The growing problem of emphysema and related disorders was the stimulus for a planned series of emphysema conferences held annually in Aspen, Colorado, beginning in 1958 ([@b46-copd-1-3]). Roger S Mitchell and his colleagues, Giles F Filley, and John R "Jack" Durrance, were the driving force that launched these landmark conferences. Financial support came from the Department of Medicine of the University of Colorado pulmonary division and local and national tuberculosis associations. The major topics of the first conference included the state-of-the-art understanding of anatomy, pathology, physiology, experimental studies, natural history, unusual forms, and allergy in relation to emphysema. JH McLean's pioneering work on bronchiolitis was and remains a highlight. Liebow described vascular injury including capillary loss in emphysema, and Loosli described loss of elastic fibers. Pierce discussed lung elastin and collagen, and Brantigan's lung volume reduction surgery was discussed as an innovative method of treating a small number of selected patients with advanced emphysema. Subsequent conferences discussed certain collateral subjects including asthma, the environment, and the lung and pulmonary circulation.

The conferences were intended to conclude after the 1964 meeting. However, the author, now on the junior faculty of the pulmonary division, and his colleagues had a burning desire to have one "last" conference on the treatment of COPD. Somewhat magically, the Chronic Respiratory Disease Branch of the Public Health Service generously supported the 8th Aspen Emphysema Conference. It presented new concepts in the management of acute respiratory failure, home care and rehabilitation, pharmacologic agents in current use, and the new concept of ambulatory oxygen in the treatment of advanced COPD. Surgical resection was again discussed by Brantigan, but now with caution because of high perioperative mortality.

This conference may have been the "tipping point" in the establishment of comprehensive treatment for COPD ([@b63-copd-1-3]). Because of the success of the 8th conference, the 9th, 10th, and 11th conferences were held annually at the same venue. These three conferences dealt with the mushrooming advances in research in COPD during that era. At the 9th conference Ben Burrows and Charles Fletcher presented their concept of "The bronchial and emphysematous types of chronic obstructive lung disease in London and Chicago", pointing out that the same disease spectrum was found on both sides of the Atlantic. This work was also published elsewhere ([@b16-copd-1-3]). Fletcher gave his initial findings on "Prognosis in chronic bronchitis".

Subsequent conferences, namely the 12th, 22nd, 26th, and 44th conferences, have documented great progress in our understanding of all aspects of COPD and its treatment. The 48th was the most recent Thomas L Petty Aspen Lung Conference (its present name) to discuss COPD and related disorders, and began with a clinical theme emphasizing the different COPD phenotypes.

Clinical--pathological correlations
===================================

Roger S Mitchell and colleagues began a series of studies of the pathology of alveolar and airways damage in patients, participating in an early emphysema registry, who later died and had autopsies at the University of Colorado Medical Center. The focus was mostly on mucous gland hyperplasia and inflammation of large conducting airways and loss of alveolar walls ([@b47-copd-1-3], [@b48-copd-1-3]). The lesion of bronchiolitis (small airways) inflammation was also described by [@b49-copd-1-3] in early reports.

Structure/structure--function relations in COPD
===============================================

Also using an artificial thorax to ventilate fresh post-mortem lungs, the Denver Group began a series of systematic studies that were designed to evaluate structure/function relationships and the major lesions associated with COPD, loss of alveolar walls (emphysema), and mucous gland hyperplasia (chronic bronchitis) ([@b69-copd-1-3]). By ventilating a whole fresh excised human lung that had been obtained at autopsy, and occasionally was available at the time of donation of organs for transplantation, it was possible to study lung mechanics both from lungs in subjects with no clinical lung disease and in patients with various stages of COPD. The investigators could measure many physiologic indices, including FEV~1~, FVC, maximum mid-expiratory flow, residual volume, and nitrogen washout tests, to study the physiologic expression of lesions of the small airways ([@b72-copd-1-3], [@b73-copd-1-3], [@b74-copd-1-3]). The measurement of the post-mortem FEV~1~ bore a close correlation with the FEV~1~ measured during life in the majority of patients (r=0.891), adjusted for both lungs ([@b69-copd-1-3]). Progressive grades of emphysema were associated with reductions in FEV~1~. The lesion of mucous gland hyperplasia (ie, the Reid index; [@b76-copd-1-3]) did not have a close correlation with airflow measurements. Dynamic airway collapse of the central airways was related to reductions in FEV~1~.

Accurate smoking histories were available in another series of 154 autopsied patients. Lesions of mucous gland hyperplasia and emphysema were found in nearly 50% of the smokers. Eight non-smokers also had these lesions ([@b71-copd-1-3]). Whether or not these patients had other risk factors for the development of the pathologic lesions associated with COPD is not known. This study was performed before the era of understanding the contributions of small airway pathology to airflow obstruction.

The landmark study by [@b38-copd-1-3] ushered in the era of small airways disease. To learn whether or not the nitrogen washout test would identify the lesions of small airways disease, the Denver Group performed additional studies on this and other tests that purported to identify early lesions in patients with COPD with emphysema and on the pathology of small airways ([@b72-copd-1-3], [@b73-copd-1-3], [@b74-copd-1-3]). [@b24-copd-1-3] provided his grading photomicrographs of mild, moderate, and severe inflammation and mild, moderate, and severe fibrosis of small airways. Emphysema was found to relate to a reduction in elastic recoil and in the percentage of the predicted FEV~1~ ([@b87-copd-1-3], [@b88-copd-1-3]; [@b73-copd-1-3]). Elastic recoil was inversely proportional to the closing capacity and the slope of phase III disease ([@b72-copd-1-3]). In addition, the maximum expiratory flow volume was not related to emphysema ([@b73-copd-1-3]). Fairly good correlations were found among the FEV~1~, FVC, and static lung recoil at 70% of inflation ([@b73-copd-1-3]). Increased lung size (TLC and FR) were related to loss of elastic recoils, but not to airflow obstruction ([@b74-copd-1-3]).

Numerous key studies initiated by the Montreal group (Cosio, Saetta, Angine, and others) have shown that reduced alveolar attachments, elastic recoil, and alveolar fenestrae are all interrelated and associated with smoking. Reduced elastic recoil is a major factor in the development of airflow limitation ([@b82-copd-1-3]; [@b25-copd-1-3]; [@b80-copd-1-3]).

During the course of these studies, several unusual patients with COPD were encountered, including a 29-year-old man who died of end-stage emphysema and a 19-year-old man who had severe pulmonary hypertension, emphysema, and marked narrowing of the conducting airways of the lungs. The Denver studies also identified the lesion of duct ectasia (ie, an unwinding of alveolar ducts due to loss of elastic recoil) in nonsymptomatic aged individuals ([@b79-copd-1-3]).

The natural history of COPD
===========================

Charles Fletcher devoted his life to the study of the natural history of COPD ([@b28-copd-1-3]). He recognized the risks of smoking and the accelerated rate of decline in FEV~1~ in susceptible smokers on the pathway to disabling symptoms ([@b28-copd-1-3]). He and his colleagues recognized that stopping smoking would retard the rate of FEV~1~ decline to that approaching the rates of reduction in age-related non-smokers ([@b62-copd-1-3]). This established the scientific foundation for smoking cessation in every stage of disease (see Lung Health Study) ([@b1-copd-1-3], [@b2-copd-1-3]).

Burrows and Earle described the course and prognosis of 200 patients with COPD in his classic study in Chicago ([@b15-copd-1-3]). Later, when observing similar patients in his lifelong study of prognosis of emphysema in a large population in Tucson, Arizona, he recognized that patients with a low FEV~1~/FVC percentage predicted the onset of rapid decline in FEV~1~ over time. Patients with the most rapid rate of decline had the worst prognosis. He termed this phenomenon as "The Horse Racing Effect" ([@b17-copd-1-3]). The discovery also established the importance of early identification and intervention (see section titled *The NLHEP and GOLD initiatives*).

The natural history of COPD begins with complex biochemical and cellular events in the small airways and surrounding alveoli. Early in the course, damage to the structure leads to a loss of elastic recoil ([@b81-copd-1-3]; [@b82-copd-1-3]; [@b74-copd-1-3]). The lungs begin to increase in size, and the FVC increases ([@b74-copd-1-3]). This results in early physiologic alterations that can be readily identified by simple spirometry ([@b17-copd-1-3]). By the time clinical signs are present, COPD is often in a moderate-to-advanced stage ([@b45-copd-1-3]).

Pathologic evidence of emphysema can be derived from CT studies or from resectional material, such as when solitary nodules are removed ([@b24-copd-1-3], [@b25-copd-1-3]). The most practical way to diagnose and to access the functional progress of COPD is by spirometry. The initial smoking-induced injury to the human lungs appears to be in the small conducting air passages and surrounding alveoli. When alveoli become damaged or lost, the elastic supporting structure of the lung is reduced ([Figures 1](#f1-copd-1-3){ref-type="fig"} and [2](#f2-copd-1-3){ref-type="fig"}). This results in both a loss of elastic recoil and in increased airways resistance since airways are no longer tethered by the radial traction forces of the surrounding alveolar attachments. Mural inflammation of small airways and airways remodeling also reduce the airway lumen.

Thus, the interrelated causes of airflow obstruction in COPD patients include a combination of airways inflammation and remodeling, bronchospasm, mucous hyper-secretion, and loss of elastic recoil. There is a complex interrelationship among these phenomena, which results in the progressive reduction in expiratory airflow as judged by the FEV~1~.

It deserves emphasis that early stages of emphysema are characterized by both hyperinflation and an increased FVC ([@b17-copd-1-3]; [@b74-copd-1-3]). This is the reason why the FEV~1~/FVC ratio is such a sensitive test for early stages of airflow obstruction. An FEV~1~/FVC of \<70% heralds the onset of rapid declines in FEV~1~ over the course of a 10-year period ([@b17-copd-1-3]). The time course of these changes in alveoli and small airways is illustrated in [Figure 3](#f3-copd-1-3){ref-type="fig"}. Thirty or more years of progressive loss in airflow may take place before the threshold to dyspnea on exertion occurs, which is usually at \<1.5 L/s and may be as low as 1.0 L/s in smaller persons.

Treatment of COPD: past, present, and future
============================================

Over 47 years ago, when the author graduated from medical school, the only therapies for COPD were antibiotics for pneumonia, potassium iodide used as a mucus thinner, and combination products containing ephedrine, a small amount of theophylline, and a minor amount of sedative to deal with the side effects of ephedrine. Inhaled isoproterenol began to be used in the early 1960s. In that era, oxygen was considered contraindicated, and exercise was prohibited for fear of straining the right heart. Corticosteroids were almost never used, even in cases of exacerbations of COPD. One paper in the early 1960s by Noehren, offered new hope that at least some treatments might be beneficial in emphysema. Both medical and surgical approaches to therapy were described ([@b54-copd-1-3]).

Management of acute respiratory failure
=======================================

Beginning in the early 1960s, patients with COPD began to be saved with the use of mechanical ventilators for the management of acute respiratory failure ([@b64-copd-1-3]). The development of systematic therapy for nonhospitalized patients can be traced to the 8th Aspen Emphysema Conference, which was held in June 1965 ([@b63-copd-1-3]). This was the only Aspen Emphysema Conference devoted entirely to treatment. The Denver Group presented their first observations on ambulatory oxygen at the conference. The many topics discussed by clinicians and scientists at the conference included principles of pulmonary rehabilitation, the treatment of cor pulmonale, home care for chronic pulmonary insufficiency, and surgical treatments for emphysema. The subsequent 22nd, 26th, and 42nd Aspen Lung Conferences also had COPD as their theme.

Long-term oxygen therapy (LTOT)
===============================

In the first Denver studies of ambulatory oxygen, patients with chronic stable hypoxemia experienced remarkable reductions in pulmonary hypertension and erythrocytosis, along with a great increase in exercise tolerance ([@b44-copd-1-3]). This and several other early pilot studies resulted in the design of the Nocturnal Oxygen Therapy Trial ([@b53-copd-1-3]). The Medical Research Council Clinic Trial compared 15 h of oxygen with air breathing ([@b96-copd-1-3]). Together, these two studies established the scientific basis of long-term oxygen therapy, which is the only treatment that has been proven to alter the course of disease and prognosis of patients with advanced COPD ([@b65-copd-1-3]).

Pulmonary rehabilitation
========================

Pulmonary rehabilitation evolved from that earlier era ([@b70-copd-1-3]; [@b66-copd-1-3]). The systematic use of drugs to restore pulmonary function, including bronchoactive drugs (ie, bronchodilators and corticosteroids) began to gain popularity in the 1990s. An emphasis on the importance of smoking cessation became a feature of treatment in the 1990s.

Surgery
=======

The technique of Lung Volume Reduction Surgery (LVRS), originally introduced by [@b11-copd-1-3] and was resurrected by Cooper and others in the 1990s ([@b23-copd-1-3]). A randomized controlled clinical trial completed in 2003 showed no reduction in mortality but an improved quality of life in a subset of surgical patients ([@b51-copd-1-3]). A subset of patients with primarily upper lobe disease and poor exercise tolerance following pulmonary rehabilitation did have a small but significant survival benefit ([@b51-copd-1-3]).

Lung transplantation is established for a small number of patients, due to the lack of organ availability ([@b94-copd-1-3]). Long-term survival for lung transplantation is limited by a high index of organ rejection and bronchiolitis obliterans ([@b94-copd-1-3]).

Corticosteroids and bronchodilators
===================================

Five studies ([@b59-copd-1-3]; [@b61-copd-1-3]; [@b99-copd-1-3]; [@b14-copd-1-3]; [@b95-copd-1-3]), which were conducted in the 1990s on therapy with inhaled corticosteroids have resulted in interesting and somewhat conflicting conclusions. Although a small subset of patients has a slight step-up in FEV~1~ following the administration of inhaled corticosteroids, the rate of decline in FEV~1~ was not retarded in any of the studies completed thus far. However, symptoms of cough, expectoration, and exacerbations of chronic bronchitis were significantly reduced in patients in the treatment groups compared with those in the placebo group. Symptomatic benefits need to be weighed against the possibility of systemic side effects (eg, reduced bone density) if inhaled corticosteroids are to be used in the long term ([@b95-copd-1-3]).

Improved survival in COPD using a combination of fluticasone propionate and salmeterol has been suggested in case controlled studies ([@b92-copd-1-3]; [@b89-copd-1-3]). Prospective randomized controlled studies are currently in progress to attempt to confirm these findings.

COPD as a systemic disease
==========================

It has been learned that patients with only mild stages of COPD may have significant cardiovascular physiologic impairments. These individuals cannot achieve maximum oxygen uptake or a maximum heart rate. Their exercise performance is limited and is likely due to physical de-conditioning, even in patients with only mild degrees of airflow obstruction and without hypoxemia ([@b18-copd-1-3]). We must now recognize COPD as a systemic disease and start to understand the metabolic and musculoskeletal implications of this generalized process ([@b85-copd-1-3], [@b86-copd-1-3]). COPD has been recognized as a risk factor for cardiovascular morbidity and mortality ([@b90-copd-1-3]). Thus corticosteroids may (or may not) have a beneficial role on the underlying systemic nature of COPD. Obviously this is an area that requires intense factor investigation. The pathogenesis of pulmonary hypertension in COPD and its treatment also remain a huge challenge ([@b36-copd-1-3]). We need to learn much more about the molecular genetics of COPD ([@b83-copd-1-3]). Why do only 15%--20% of smokers develop airflow obstruction ([@b83-copd-1-3])?

The Lung Health Study
=====================

Following a preliminary meeting organized by the author in 1982 during his presidency of the American College of Chest Physicians and attended by many experts who were both for or against studies of early identification, the Lung Health Study was planned and implemented by the Lung Division of the National Heart, Lung, and Blood Institute (NHLBI). In all 10 centers, 5887 volunteers were enrolled who were heavy smokers between the ages of 35 and 60, and who had any degree of airflow obstruction identified at baseline screening ([@b1-copd-1-3]). Subjects were randomized to receive special care or usual care in a 2:1 ratio. Half of the subjects randomized to special care received ipratropium bromide and the other half an identical placebo inhaler. The initial report of outcome showed that 22% of patients who received special care stopped smoking as part of the study, compared with 5% in the usual care group. Patients who succeeded in stopping had a small improvement in FEV~1~ initially, followed by a slow decline up to five years of follow-up ([Figure 4](#f4-copd-1-3){ref-type="fig"}). Ipratropium did not improve baseline lung function, but did increase airflow on each day that it was tested over the course of the study.

The most common cause of death was lung cancer (57), compared with 37 cardiac deaths and 55 deaths from all other cancers (N=149). At a 14.5-year follow-up, the most common cause of death remained lung cancer (33%), with cardiovascular deaths the second most common cause of death (22%). Coronary artery disease was also a common cause of death but the death records had an overlap with the designation of cardiovascular deaths. Seven point 8 percent (7.8%) died of nonmalignant respiratory disease. Two point three percent (2.3%) died of unknown causes. This powerful study showed conclusively that stopping smoking in middle age ([@b2-copd-1-3]) was associated with a much better survival than in patients who continued to smoke. This study and others form the scientific basis for early identification of COPD and related disorders, the most common of which is lung cancer.

The NLHEP and GOLD initiatives
==============================

Following a preliminary planning meeting in 1993 and a comprehensive workshop on COPD sponsored by the Lung Division of the NHLBI, the need for a new national health initiative for the early diagnosis, treatment, and research in COPD was launched in a major publication ([@b75-copd-1-3]) and later on gained full support in *CHEST (*[@b67-copd-1-3]). Soon thereafter, the National Lung Health Education Program (NLHEP) was founded by the author, who was its first chairman. Initial NIH support was supplemented by unrestricted grants from the pharmaceutical industry. All major societies with a stake in COPD sent representatives to the biennial board of directors meeting held at the times of the American College of Chest Physicians and ATS. Numerous publications and recommendations followed. The most notable was the consensus's statement of the NLHEP, which recommended the spirometric testing of all smokers aged 45 or older and anyone with chronic cough, dyspnea on exertion, mucus hypersecretion, or wheeze ([@b29-copd-1-3]). This helped promote the development of accurate and inexpensive office spirometers for widespread use. In 2004, the NLHEP's administrative functions were transferred to the American Association for Respiratory Care (AARC), and a new Chairman, Professor Dennis Doherty of the University of Kentucky, succeed the author, who remains Chairman Emeritus and is still actively involved ([@b68-copd-1-3]).

In 2001, the Global Initiative of Obstructive Lung Disease (GOLD) was launched by the WHO and NHLBI ([@b60-copd-1-3]; [@b32-copd-1-3]). International in scope, GOLD offered a new classification of the severity of COPD, which is now accepted by most societies and organizations. Together, the NLHEP and GOLD will continue to raise awareness of the importance of COPD and promote early identification and intervention.

Recent biologic studies and therapeutic targets
===============================================

The pathogenesis of COPD is complex and involves multiple mechanisms. The bottom line of these processes is inflammatory damage of the conducting airways and vascular damage of the alveolar surface of the lung, which constitutes the air--blood interface. Capillary damage leads to loss of both alveolar walls and reduced elastic recoil. Inflammatory obstruction of small airways contributes to airflow obstruction; the loss of alveolar walls and airflow obstruction (as Laënnec first described) are part and parcel of the pathogenesis.

The inflammatory process of COPD is initiated by inhalation of noxious gases in cigarette smoke and in the environment. All airways, including the central airways, become inflamed, which results in mucous gland hyperplasia and hypersecretion. Macrophages and CD8 cells are the prime cellular mediators, which include leukotriene B~4~, interleukin-8, and tumor necrosis factor (TNF) ([@b7-copd-1-3]). Thus, the inflammatory processes of COPD are markedly different from those of asthma. Inflammation in asthma consists of more corticosteroid-responsive cells and mediators, such as mast cell-activated eosinophils, T-helper type 2 lymphocytes (CD4 phenotype), and a number of cytokines whose production is decreased by use of corticosteroids. This may explain, at least in part, why patients with COPD are not nearly as responsive as patients with asthma to both inhaled and systemic steroids.

The protease--antiprotease imbalance is certainly true in the alpha-1-antitrypsin deficiency state. Matrix metalloproteinases, collagenases, and other tissue-degrading enzymes are released from macrophages and neutrophils. An oxidant--antioxidant imbalance also exists in small airways and at the air--blood interface. How this can be dealt with therapeutically remains a challenge. Potentially, many other mechanisms (including processes that trigger mucus hypersecretion or cause dysfunction) and inhibition of growth factors (such as vascular endothelial growth factor at a reduced level) result in premature apoptosis of capillaries and the alveolar walls they nourish ([@b40-copd-1-3]). Phosphodiester 4 inhibitors are a new class of drugs that may oppose or otherwise modify the basic inflammatory processes of the small and large airways. Specific cytokine antagonists (eg, 1, 2, and 3) on TNF2 inhibitors are the subject of current investigations ([@b7-copd-1-3]). Systemic clinical approaches to patients with COPD and cardiovascular disease are emerging ([@b92-copd-1-3]; [@b78-copd-1-3]; [@b90-copd-1-3]). All of this new knowledge about the pathogenesis of emphysema and related airway inflammation promises new therapeutic targets for the future.

Summary
=======

The evolution of our understanding of emphysema and chronic bronchitis covers nearly four centuries. Anatomists, clinical scientists from many disciplines, and clinicians have contributed to the knowledge that an attack on alveoli and both large and small airways contribute to the emergence of chronic and ultimately irreversible airflow limitation, due to loss of elastic recoil and increase in airflow resistance through the complex conducting system of the lungs.

Dyspnea is due primarily to abnormal lung and thoracic mechanics and the increased work of breathing. Cough and mucus hypersecretion are due to inflammation, mucous gland hyperplasia, and goblet cell hyperplasia. One or more host factors are involved in many patients, and family clustering may go beyond alpha-one-antitrypsin deficiency. COPD must be considered a systemic disease.

Treatment requires an elimination of smoking and other irritants in the environment. Such measures forestall or prevent the premature loss of ventilatory function and loss of blood gas homeostasis.

Treatment of symptomatic disease, beyond smoking cessation requires the use of bronchodilators and probably corticosteroids. Pulmonary rehabilitation and oxygen improve the quality and length of life in selected patients. Lung volume reduction surgery improves lung mechanics and reduces dyspnea by improving elastic recoil, which affects both airflow and perfusion, thus ameliorating gas exchange abnormalities in selected patients. Lung transplantation helps a few patients.

The future requires early identification and intervention in the basic disease processes. Spirometry must emerge as the fundamental way to diagnose and monitor responses to therapy. It must be employed by all who care for patients with COPD. New therapies must reduce both alveolar damage and inflammation of the airways. The future for COPD science and improved prevention and patient care appears bright.
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